igf 1 lr3 achat IGF1 | IGF1 Peptide | Recombinant Human IGF-1 LR3 – Research Peptide

discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data

Researchers typically reference the literature for each peptide separately the receptor-binding profile of the GHRH analogue and the selectivity profile of the GHRP and use the co-lyophilised vial as a methodological convenience

Research published in Growth Hormone & IGF Research demonstrates that the growth hormone secretagogue ipamorelin counteracts the catabolic effects of glucocorticoids on skeletal muscles

typically resolves with proper technique